glp-1 clinical trials sign up Foundation GLP-1 Drug Pipeline 2026 |

No modifications to standard patient preparation protocols were made for these cases

Tirzepatide (Mounjaro, Zepbound) Strengths: Highest efficacy for both glucose control and weight loss Dual mechanism (GLP-1 + GIP) may provide unique benefits Once-weekly dosing Generally well-tolerated Considerations: Higher cost than semaglutide Less long-term safety data (newer medication) Cardiovascular outcome trial not yet complete (though expected to be positive) Best for: Patients prioritizing maximum weight loss

Other care products include bath and body items, hair care, shaving and grooming accessories or teeth whitening kits

DIO: diet-induced obesity